Studies in human have shown that a polymorphism in an upstream enhancer element either generates or disrupts a binding site for AP-2 proteins, with the latter variant increasing the risk for orofacial clefting (Rahimov et al., 2008). Here, TFAP2A is linked to orofacial cleft.